The two newer cases seen were in Europe versus the US.  In the US, qualifying patients must be seriously screened and followed during chronic administration of this drug.  The FDA was strict on this coming out of banning use!

 

In the EU, the label was weaker and lead to doctors doing the screening but slacking off on the follow-up.  The condition seems to appear in increasing numbers later in administration (related to the immune system changes that occur) and if monitored closely can be caught before it becomes serious.

 

Therefore the EU needs to tighten requirements for patient monitoring!  I seriously doubt anything is coming of the Tysabri situation in the US at all!

 

Just a bit under a couple grand ahead to date.  Have not decided how far to take this?  You got the buyout rumors, the selling of a division out there, and classic recovery in the PPS over an overreaction?

 

We will see!  It was my biggest winner today.

 

Kutz